One‐Two Punch Therapy for the Treatment of T‐Cell Malignancies Involving p53‐Dependent Cellular Senescence
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Abstract
T‐cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug‐induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well‐known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T‐cell malignancies with nonlethal concentration. Transcription activity of senescence‐suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin‐induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin‐induced aging process. Results showed that wogonin increased the activity of senescence‐associated β‐galactosidase (SA‐β‐Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL‐2 in senescent T‐cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL‐2 inhibitor Navitoclax (ABT‐263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin‐induced senescent cells. Thus, the “one‐two punch” approach increased the sensibility of T‐cell malignancies with low expression of BCL‐2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T‐cell malignancies.Keywords
Funding Information
- China Postdoctoral Science Foundation (2018M642373)
- Natural Science Foundation of Jiangsu Province (BE2018711, BK20190560)
- National Natural Science Foundation of China (81673461, 81503096, 81903647, 81830105, 81873046)
This publication has 74 references indexed in Scilit:
- Telomerase: central regulator of all of the hallmarks of cancerTrends in Biochemical Sciences, 2013
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16BNature Medicine, 2012
- Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsBlood, 2012
- New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer TherapyJournal of Biomedicine and Biotechnology, 2012
- DNA double-strand break repair pathways, chromosomal rearrangements and cancerSeminars in Cell & Developmental Biology, 2011
- Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cellsMechanisms of Ageing and Development, 2009
- Both telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescenceEpigenetics & Chromatin, 2008
- Living on a break: cellular senescence as a DNA-damage responseNature Reviews Cancer, 2008
- BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemiaBlood, 2008
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737Journal of Clinical Investigation, 2007